Hurley Capital’s Biogen BIIB Stock Holding History

Hurley Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2	Closed	-$280	–	611
2025 Q3	$280	Buy	+2	New	+$270	﹤0.01%	635
2025 Q2	–	Sell	-10	Closed	-$1.37K	–	469
2025 Q1	$1.37K	Buy	+10	New	+$1.43K	﹤0.01%	436

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hurley Capital's BIIB Position: Q4 2025 in Review

Hurley Capital sold out of Biogen (BIIB) in Q4 2025, closing a stake of 2 shares — an estimated $280 sold.

Hurley Capital first reported a position in BIIB in Q1 2025 and held it in 2 quarters. The position peaked at $1.37K in Q1 2025. 999 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

Hurley Capital reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
Hurley Capital sold 2 Biogen shares in Q4 2025, an estimated $280.
Hurley Capital first reported a position in Biogen in Q1 2025 and held it in 2 quarters.
Hurley Capital's Biogen position peaked at $1.37K in Q1 2025.
999 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Hurley Capital's 13F filing for Q4 2025, filed 17 Feb 2026.